FDA Recommends Genetic Testing For Plavix, Opens Window For Effient
Executive Summary
FDA's latest revision to Plavix labeling on the issue of poor response in slow metabolizers has heightened the concerns to the highest level - that of a "black box" warning - and recommends use of testing to identify genetic differences in patients' metabolizing function. But FDA officials note that the testing won't be practical in all treatment settings - which leaves another opening for Lilly/Daiichi Sankyo to push use of their competitor Effient
You may also be interested in...
For Effient And Brilinta, A Formidable Competitor Grows More So
Plavix was a tough competitor before it went generic; now that cheap versions of the clot-buster are available, the market will prove even more challenging for the remaining branded antiplatelet drugs.
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.
Will Plavix Testing Be Enough To Limit Use Of Newer Antiplatelet Drugs?
The role of newer antiplatelet agents such as Effient (prasugrel) is partly dependent on the prospects for optimizing Plavix (clopidogrel), but the feasibility of using diagnostic tests to make sure the soon-to-be generic drug is working properly remains a matter of debate in cardiology.